Weekly Doxorubicin and Continuous Infusional 5-Fluorouracil for Advanced Breast Cancer
Author Information
Author(s): H Gabra, DA Cameron, LE Lee, J Mackay, RCF Leonard
Primary Institution: ICRF Medical Oncology Unit and Longmore Breast Unit, Edinburgh Breast Group, Western General Hospital, Edinburgh, UK
Hypothesis
Can a regimen of weekly doxorubicin and continuous infusional 5-fluorouracil improve treatment outcomes for patients with advanced breast cancer?
Conclusion
The AcF regimen is highly active in breast cancer with acceptable toxicities and can be used before alkylating agent-based high-dose therapy.
Supporting Evidence
- 76% of assessable patients achieved UICC response criteria.
- 20% of patients had a complete response.
- Median survival was 13 months.
- 62% of patients were chemonaive.
Takeaway
Doctors tested a new way to give two cancer drugs to help patients with advanced breast cancer feel better and live longer. Most patients got better, and the side effects were manageable.
Methodology
This was a non-randomised single arm phase II study where patients received a combination of doxorubicin and 5-fluorouracil for at least 6 weeks.
Potential Biases
Potential bias due to the non-randomised design and the single-arm nature of the study.
Limitations
The study was non-randomised and had a small sample size, which may limit the generalizability of the results.
Participant Demographics
Patients were 60 years of age or less with a confirmed diagnosis of breast carcinoma, either loco-regionally recurrent or metastatic.
Statistical Information
P-Value
0.03
Confidence Interval
95% confidence interval, 62-87%
Statistical Significance
p=0.03
Want to read the original?
Access the complete publication on the publisher's website